多西他赛联合阿帕替尼二线治疗进展期非小细胞肺癌的临床效果  

Clinical effect of Docetaxel combined with Apatinib in the second-line treatment of advanced non-small cell lung cancer

作　　者：徐芹 鲍瑜[2] 亢晓彬[1] XU Qin;BAO Yu;KANG Xiaobin(Department of Pharmacy,Chizhou People′s Hospital,Anhui Province,Chizhou247000,China;Department of Oncology,Chizhou People′s Hospital,Anhui Province,Chizhou247000,China)

机构地区：[1]安徽省池州市人民医院药剂科,安徽池州247000 [2]安徽省池州市人民医院肿瘤科,安徽池州247000

出　　处：《中国医药导报》2020年第23期95-98,共4页China Medical Herald

基　　金：安徽省科技计划项目(1706g08533)。

摘　　要：目的探讨多西他赛联合阿帕替尼二线治疗进展期非小细胞肺癌(NSCLC)临床效果。方法选取安徽省池州市人民医院于2017年1月—2019年10月收治的NSCLC患者80例。将其按照随机数字表法分为对照组(40例)和研究组(40例)。对照组予以多西他赛化疗,研究组予以阿帕替尼联合多西他赛化疗,两组均治疗4个疗程。比较两组临床疗效、血清肿瘤指标以及生活质量,统计两组不良反应发生情况。结果研究组治疗后临床总有效率高于对照组(P<0.05)。治疗后,两组癌胚抗原、鳞状上皮细胞癌抗原、糖蛋白抗原125较治疗前均降低,且研究组低于对照组(P<0.05)。治疗后,两组生活质量评分均升高,且研究组高于对照组(P<0.05)。两组不良反应发生率比较差异无统计学意义(P>0.05)。结论多西他赛联合阿帕替尼二线治疗进展期NSCLC的效果显著,可有效改善患者生活质量,阻止疾病进展,且安全性较好。Objective To investigate the clinical effect of Docetaxel combined with Apatinib in the second-line treatment of advanced non-small cell lung cancer(NSCLC).Methods A total of 80 NSCLC patients admitted to Chizhou People′s Hospital from January 2017 to October 2019 were selected and they were divided into control group(40 cases)and study group(40 cases)by random number table method.The control group was treated with Docetaxel chemotherapy,while the study group was treated with Apatinib and Docetaxel chemotherapy,both groups were treated for four courses.The clinical efficacy,serum tumor markers and quality of life of the two groups were compared.The adverse reactions in the two groups were statisticsed.Results The total clinical effective rate of the study group was higher than that of the control group(P<0.05).After treatment,carcinoembryonic antigen,squamous cell carcinoma antigen and glycoprotein antigen 125 in both groups were decreased compared with before treatment,and the study group was lower than the control group(P<0.05).After treatment,the quality of life scores of both groups increased,and the study group was higher than the control group(P<0.05).There was no significant difference in the incidence of adverse reactions between the two groups(P>0.05).Conclusion Docetaxel combined with Apatinib as the second-line treatment of advanced NSCLC has significant curative effect,it can effectively improve the quality of life of patients,and prevent disease progression,and has good safety.

关 键 词：多西他赛 阿帕替尼 进展期 非小细胞肺癌 疗效 

分 类 号：R734.2[医药卫生—肿瘤]